Trifluoperazine
Basic Information
| Item | Value |
|---|---|
| DrugBank ID | DB00831 |
| Evidence Level | L5 (Computational Prediction) |
| Number of Predicted Indications | 18 |
Predicted Indications (TxGNN)
The following are potential new indications predicted by the TxGNN model. Higher scores indicate higher predicted relevance.
| # | Indication | Source |
|---|---|---|
| 1 | manic bipolar affective disorder | KG + DL |
| 2 | syndromic myopia | KG + DL |
| 3 | myopia X-linked | KG + DL |
| 4 | retinal dystrophy with or without extraocular anomalies | KG + DL |
| 5 | polymicrogyria, perisylvian, with cerebellar hypoplasia and arthrogryposis | KG + DL |
| 6 | Charcot-Marie-Tooth disease, demyelinating, type 1G | KG + DL |
| 7 | congenital disorder of glycosylation with defective fucosylation | KG + DL |
| 8 | hydranencephaly (disease) | KG + DL |
| 9 | myopia 26, X-linked, female-limited | KG + DL |
| 10 | atypical glycine encephalopathy | KG + DL |
| 11 | bipolar disorder | KG + DL |
| 12 | major affective disorder | KG + DL |
| 13 | distal 17p13.3 microdeletion syndrome | KG + DL |
| 14 | agoraphobia | KG + DL |
| 15 | benign paroxysmal torticollis of infancy | KG + DL |
| 16 | anxiety disorder | KG + DL |
| 17 | psychotic disorder | KG + DL |
| 18 | REM sleep behavior disorder | KG + DL |
Disclaimer
These predictions are for research purposes only and do not constitute medical advice. Clinical validation is required before any clinical application.